FDA Approves DANZITEN — Azurity Pharmaceuticals, Inc.

On November 7, 2024, Azurity Pharmaceuticals received FDA approval for Danziten (nilotinib), expanding access to this oral therapy amid a competitive climate for chronic myeloid leukemia management. This development signals Azurity's strategic deepening of its specialized oncology portfolio, though immediate market implications remain constrained by Zyclara’s dominant commercial presence.